Animal Drug Compounding Market

Animal Drug Compounding Market (Product: Anti-infectives, Anti-inflammatory, CNS Agents, GI Drugs, and Others; and Route of Administration: Oral, Injectable, Topical, Rectal, and Ocular) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Animal Drug Compounding Market Outlook 2031

  • The global animal drug compounding market was valued at US$ 1.1 Bn in 2021
  • The global market is projected to grow at a CAGR of 7.4% between 2022 and 2031
  • The global animal drug compounding market is anticipated to be reach more than US$ 2.4 Bn by the end of 2031

Analysts’ Viewpoint on Animal Drug Compounding Market Scenario

Animal medicine compounding stakeholders have benefited significantly owing to rapid advancements in production techniques and growth in the pharmaceutical & biotechnology industry. People have become more conscious of the importance of improving animal health, which has increased the demand for veterinary medicine compounding. Officially approved drugs are not always available; hence, compounded medication is a better option for treating a wide range of illnesses. Chewable tablets, for example, are commercially approved products in specific dosage forms and are recommended for usage in specific animal species. The animal drug compounding market has matured due to the increase in owner approval of the practice in the past few years. Key players operating in the market are focusing on partnerships and collaborations to expand their global footprint.

Animal Drug Compounding Market

Animal Drug Compounding Market Introduction

Animal drug compounding is the method of combining, blending, or modifying ingredients to produce a medicine tailored to the needs of a single or small group of animals. These drugs can be used in veterinary medicine. These drugs are typically prepared by pharmacists or veterinarians. Compounded animal drug companies are working harder to maintain a steady supply of chemical compounds and materials to support veterinary compounding. Letco Medical, a provider of pharmaceutical ingredients, is now able to support a formula database that assists in choosing the ideal combination for any animal. Suppliers of APIs, bases, flavors, and formula for veterinary compounding collaborate closely with businesses that produce animal drugs.

Request a sample to get extensive insights into the Animal Drug Compounding Market

Rise in Number of Licensed Veterinarians and Pharmacists Driving Animal Drug Compounding Market Growth

Increase in number of people who own pets has led to the growth of the pharmacy practice of veterinary pharmacists who compound medications or assist pharmacists in producing compounded pet medications. Compounded medications are used to avoid allergens found in animals such as lactose, gluten, dyes, preservatives, and sugars. A veterinarian with knowledge of compounded medications could help in cases where discontinued medications are urgently needed. Governments of several countries are funding programs, fellowships, and grants to help pharmacists develop the necessary skills for medication compounding. For instance, Brazil has 7,211 compounding pharmacies and 16,000 compounding pharmacists.

The EAHP encourages health authorities in Europe to facilitate the transfer of drug store preparations among hospitals and invest in compounding services, as only healthcare facilities are able to respond to patients’ needs and extraordinary situations such as shortage of essential medicines. This is expected to create new opportunities in the market in the next few years.

Increase in Demand for Companion Animals Fueling Global Animal Drug Compounding Market

The global companion animal population has increased in the past few years. The American Veterinary Medical Association (2017-2018 - U.S. Pet Ownership & Demographics Sourcebook) reported that 38.4% of households have dogs and 25.4% have cats. According to FEDIAF, 85 million households in the country own at least one pet animal, with pet-related services and products totaling EUR 19.7 Bn. Similarly, demand for companion animals is high in Brazil, India, China, and Singapore.

Rise in demand for exotic companion animals is driving the need for compounded medication in order to meet their personalized medical care needs. Animals cannot always be treated with the same medications as humans. Compounded medications are used for specific animals, as these can be tailored to the needs of each individual animal. Making medications more palatable by adding flavors and colors is a service that is especially beneficial for pets. Farmers and ranchers use medicines to ensure the health of their livestock, protect public health, and safeguard the food supply.

Request a custom report on Animal Drug Compounding Market

Treatment of Minor as well as Serious Infectious Diseases Bolstering Anti-infectives Segment

In terms of product, the anti-infectives segment is expected to grow at a rapid pace during the forecast period. Anti-infectives, which include antibacterial, antiviral, antifungal, and antiphrastic medications, work to prevent or treat infections. These drugs treat minor infections, and in most cases, cure serious infectious diseases such as pneumonia or tuberculosis. Routine procedures and complex surgeries pose a serious infection risk. Compounding allows to prescribe accurate doses when treating animal patients in need. This is anticipated to propel the anti-infectives segment during the forecast period.

Surge in Number of Companion Animals Across Globe

Based on animal type, the companion animal segment dominated the global market in 2021. Dogs and cats are highly common companion animals. More than 60% of households have cats or dogs as companion animals. As per market trends, market players are striving to diversify their product portfolio through R&D, product launches, and other strategic initiatives. For instance, IDEXX Laboratories, a pet healthcare, veterinary diagnostics, and veterinary practice software company, provides a diverse range of tests, devices, and services for companion animal specialty drugs.

Better Chemical Stability and Faster Dissolution Fueling Powders Segment

In terms of dosage form, the powders segment dominated the global market in 2021. Powders have better chemical stability than liquids and dissolve faster than tablets or capsules. This is a key factor driving the segment. Powder dosage forms have greater physicochemical stability and longer shelf life than liquid dosage forms. Oral powders containing water-soluble drugs dissolve faster than tablets or capsules, which require the disintegration of the tablet or capsule shell prior to dissolution.

High Adoption Rate of Oral Route of Administration

Based on route of administration, the oral segment is projected to dominate the global market in 2021. The oral route of administration is commonly used for companion and food animals. Tablets, capsules, solutions, and suspensions are common oral medications for dogs and cats; pastes are also applied to cats' forelimbs, where they are licked and consumed.

Regional Outlook of Animal Drug Compounding Market

North America accounted for around 40.0% share of the global market in 2021. Well-established healthcare infrastructure and rapid adoption of newer therapeutic strategies are expected to propel the market in the region in the near future. The U.S. is anticipated to account for major share of the market in North America due to presence of large chain pharmacies. The U.S. market is anticipated to be driven by technological advancements in highly efficient, precise, and automatic integrated compounding machines during the forecast period. Rise in cost of drugs and preference for customized drug preparation are expected to propel the market in North America in the near future.

The animal drug compounding market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Rise in acceptance of compounded veterinary planning and preparation is the key factor that is anticipated to increase the market size for animal drug compounding in the region. Moreover, surge in pet ownership is likely to drive the market size in Asia Pacific during the forecast period.

Analysis of Key Players in Global Animal Drug Compounding Market

The global market is consolidated, with the presence of a small number of dominant players. Strategic alliances are being formed by key players in order to increase revenue and market share. Product line expansion and acquisitions & mergers are the other strategies used by players to expand their business footprint. Prominent players operating in the global animal drug compounding market are Custom Med Compounding Pharmacy, Triangle Compounding Pharmacy, Wellness Pharmacy of Cary, Wedgewood Pharmacy, Central Compounding Center South, Millers Pharmacy, Davis Islands Pharmacy, Smith's Pharmacy, Caringbah Compounding Pharmacy, Specialist Compounding Pharmacy Pte Ltd., and Tache Pharmacy.

Key Developments in Animal Drug Compounding Market

  • In March 2021, Osceola Capital and seasoned businessman Jacob Beckel announced the formation of Revelation Pharma Corp to investigate investments and strategic partnerships in the pharmacy compounding market
  • In December 2020, Wedgewood Pharmacy and Partners Group agreed to replace New Harbor Capital as the majority shareholder

Key players have been profiled in the market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Animal Drug Compounding Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 1.1 Bn

Market Forecast Value in 2031

More than US$ 2.4 Bn

Growth Rate

(CAGR) for 2022-2031

7.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and key trend analysis.

Competition Landscape

  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Anti-infectives
      • Metranidazole
      • Ketaconazole
      • Others
    • Anti-inflammatory
      • Prednisolone
      • Tramadol
      • Others
    • CNS Agents
      • Potassium Bromide
      • Gabapentin
      • Other CNS Agents
    • GI Drugs
      • Apomorphine
      • Ursodiol
      • Cisapride
      • Other GI Drugs
    • Others
      • Methimazole
      • Others
  • Animal Type
    • Companion Animal
      • Dogs
      • Cats
      • Others
    • Livestock
  • Dosage Form
    • Capsules
    • Solutions
    • Powders
    • Suspension
    • Others
  • Route of Administration
    • Oral
    • Injectable
    • Topical
    • Rectal
    • Ocular
  • Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Wedgewood Pharmacy
  • Triangle Compounding Pharmacy
  • Davis Islands Pharmacy
  • Custom Med Compounding Pharmacy
  • Central Compounding Center South
  • Wellness Pharmacy of Cary
  • Caringbah Compounding Pharmacy
  • Millers Pharmacy, Smith's Pharmacy
  • Specialist Compounding Pharmacy Pte Ltd.
  • Tache Pharmacy

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global animal drug compounding market in 2021?

The global animal drug compounding market was valued at US$ 1.1 Bn in 2021

How big will be the global animal drug compounding market in 2031?

The global animal drug compounding market is projected to reach more than US$ 2.4 Bn by 2031

What will be the CAGR of the global animal drug compounding market during the forecast period (2022–2031)?

The global animal drug compounding market is anticipated to grow at a CAGR of 7.4% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in demand for companion animals and focus of manufacturers on drug dose adjustment & taste altering

What is the share of the leading segment of the global animal drug compounding market?

The CNS agents product segment held more than 40.0% share of the global market in 2021

Who are the prominent players in the global Animal drug compounding market?

Wedgewood Pharmacy, Triangle Compounding Pharmacy, Davis Islands Pharmacy, Custom Med Compounding Pharmacy, Central Compounding Center South, Wellness Pharmacy of Cary, Caringbah Compounding Pharmacy, Millers Pharmacy, Smith's Pharmacy, Specialist Compounding Pharmacy Pte Ltd., and Tache Pharmacy

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Animal Drug Compounding Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Animal Drug Compounding Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Regulatory Scenario by Region/globally

        5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

        5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global Animal Drug Compounding Market Analysis and Forecast, by Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product, 2017–2031

            6.3.1. Anti-invectives

                6.3.1.1. Metranidazole

                6.3.1.2. Ketaconazole

                6.3.1.3. Other Anti invectives

            6.3.2. Anti-inflammatory

                6.3.2.1. Prednisolone

                6.3.2.2. Tramadol

                6.3.2.3. Others

            6.3.3. CNS Agents

                6.3.3.1. Potassium bromide

                6.3.3.2. Gabapentin

                6.3.3.3. Other CNS agents

            6.3.4. GI Drugs

                6.3.4.1. Apomorphine

                6.3.4.2. Ursodiol

                6.3.4.3. Cisapride

                6.3.4.4. Other GI Drugs

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Product

    7. Global Animal Drug Compounding Market Analysis and Forecast, by Animal Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Animal Type, 2017–2031

            7.3.1. Companion Animal

                7.3.1.1. Dogs

                7.3.1.2. Cats

                7.3.1.3. Others

            7.3.2. Live Stock

        7.4. Market Attractiveness Analysis, by Animal Type

    8. Global Animal Drug Compounding Market Analysis and Forecast, by Dosage Form

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Dosage Form, 2017–2031

            8.3.1. Capsules

            8.3.2. Solutions

            8.3.3. Powders

            8.3.4. Suspension

            8.3.5. Others

        8.4. Market Attractiveness Analysis, by Dosage Form

    9. Global Animal Drug Compounding Market Analysis and Forecast, by Route of Administration

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Route of Administration, 2017–2031

            9.3.1. Oral

            9.3.2. Injectable

            9.3.3. Topical

            9.3.4. Rectal

            9.3.5. Ocular

        9.4. Market Attractiveness Analysis, by Route of Administration

    10. Global Animal Drug Compounding Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Animal Drug Compounding Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Anti-infectives

                11.2.1.1. Metranidazole

                11.2.1.2. Ketaconazole

                11.2.1.3. Other Anti-infectives

            11.2.2. Anti-inflammatory

                11.2.2.1. Prednisolone

                11.2.2.2. Tramadol

                11.2.2.3. Others

            11.2.3. CNS Agents

                11.2.3.1. Potassium bromide

                11.2.3.2. Gabapentin

                11.2.3.3. Other CNS agents

            11.2.4. GI Drugs

                11.2.4.1. Apomorphine

                11.2.4.2. Ursodiol

                11.2.4.3. Cisapride

                11.2.4.4. Other GI Drugs

            11.2.5. Others

        11.3. Market Value Forecast, by Animal Type, 2017–2031

            11.3.1. Companion Animal

                11.3.1.1. Dogs

                11.3.1.2. Cats

                11.3.1.3. Others

            11.3.2. Live Stock

        11.4. Market Value Forecast, by Dosage Form, 2017–2031

            11.4.1. Capsules

            11.4.2. Solutions

            11.4.3. Powders

            11.4.4. Suspension

            11.4.5. Others

        11.5. Market Value Forecast, by Route of Administration, 2017–2031

            11.5.1. Oral

            11.5.2. Injectable

            11.5.3. Topical

            11.5.4. Rectal

            11.5.5. Ocular

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Product

            11.7.2. By Animal Type

            11.7.3. By Dosage Form

            11.7.4. By Route of Administration

            11.7.5. By Country

    12. Europe Animal Drug Compounding Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017–2031

            12.2.1. Anti-infectives

                12.2.1.1. Metranidazole

                12.2.1.2. Ketaconazole

                12.2.1.3. Other Anti-infectives

            12.2.2. Anti-inflammatory

                12.2.2.1. Prednisolone

                12.2.2.2. Tramadol

                12.2.2.3. Others

            12.2.3. CNS Agents

                12.2.3.1. Potassium bromide

                12.2.3.2. Gabapentin

                12.2.3.3. Other CNS agents

            12.2.4. GI Drugs

                12.2.4.1. Apomorphine

                12.2.4.2. Ursodiol

                12.2.4.3. Cisapride

                12.2.4.4. Other GI Drugs

            12.2.5. Others

        12.3. Market Value Forecast, by Animal Type, 2017–2031

            12.3.1. Companion Animal

                12.3.1.1. Dogs

                12.3.1.2. Cats

                12.3.1.3. Others

            12.3.2. Live Stock

        12.4. Market Value Forecast, by Dosage Form, 2017–2031

            12.4.1. Capsules

            12.4.2. Solutions

            12.4.3. Powders

            12.4.4. Suspension

            12.4.5. Others

        12.5. Market Value Forecast, by Route of Administration, 2017–2031

            12.5.1. Oral

            12.5.2. Injectable

            12.5.3. Topical

            12.5.4. Rectal

            12.5.5. Ocular

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Product

            12.7.2. By Animal Type

            12.7.3. By Dosage Form

            12.7.4. By Route of Administration

            12.7.5. By Country/Sub-region

    13. Asia Pacific Animal Drug Compounding Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017–2031

            13.2.1. Anti-infectives

                13.2.1.1. Metranidazole

                13.2.1.2. Ketaconazole

                13.2.1.3. Other Anti-infectives

            13.2.2. Anti-inflammatory

                13.2.2.1. Prednisolone

                13.2.2.2. Tramadol

                13.2.2.3. Others

            13.2.3. CNS Agents

                13.2.3.1. Potassium bromide

                13.2.3.2. Gabapentin

                13.2.3.3. Other CNS agents

            13.2.4. GI Drugs

                13.2.4.1. Apomorphine

                13.2.4.2. Ursodiol

                13.2.4.3. Cisapride

                13.2.4.4. Other GI Drugs

            13.2.5. Others

        13.3. Market Value Forecast, by Animal Type, 2017–2031

            13.3.1. Companion Animal

                13.3.1.1. Dogs

                13.3.1.2. Cats

                13.3.1.3. Others

            13.3.2. Live Stock

        13.4. Market Value Forecast, by Dosage Form, 2017–2031

            13.4.1. Capsules

            13.4.2. Solutions

            13.4.3. Powders

            13.4.4. Suspension

            13.4.5. Others

        13.5. Market Value Forecast, by Route of Administration, 2017–2031

            13.5.1. Oral

            13.5.2. Injectable

            13.5.3. Topical

            13.5.4. Rectal

            13.5.5. Ocular

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Product

            13.7.2. By Animal Type

            13.7.3. By Dosage Form

            13.7.4. By Route of Administration

            13.7.5. By Country/Sub-region

    14. Latin America Animal Drug Compounding Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017–2031

            14.2.1. Anti-infectives

                14.2.1.1. Metranidazole

                14.2.1.2. Ketaconazole

                14.2.1.3. Other Anti-infectives

            14.2.2. Anti-inflammatory

                14.2.2.1. Prednisolone

                14.2.2.2. Tramadol

                14.2.2.3. Other Anti-inflammatory

            14.2.3. CNS Agents

                14.2.3.1. Potassium bromide

                14.2.3.2. Gabapentin

                14.2.3.3. Other CNS agents

            14.2.4. GI Drugs

                14.2.4.1. Apomorphine

                14.2.4.2. Ursodiol

                14.2.4.3. Cisapride

                14.2.4.4. Other GI Drugs

            14.2.5. Others

        14.3. Market Value Forecast, by Animal Type, 2017–2031

            14.3.1. Companion Animal

                14.3.1.1. Dogs

                14.3.1.2. Cats

                14.3.1.3. Others

            14.3.2. Live Stock

        14.4. Market Value Forecast, by Dosage Form, 2017–2031

            14.4.1. Capsules

            14.4.2. Solutions

            14.4.3. Powders

            14.4.4. Suspension

            14.4.5. Others

        14.5. Market Value Forecast, by Route of Administration, 2017–2031

            14.5.1. Oral

            14.5.2. Injectable

            14.5.3. Topical

            14.5.4. Rectal

            14.5.5. Ocular

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Product

            14.7.2. By Animal Type

            14.7.3. By Dosage Form

            14.7.4. By Route of Administration

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Animal Drug Compounding Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Product, 2017–2031

            15.2.1. Anti-infectives

                15.2.1.1. Metranidazole

                15.2.1.2. Ketaconazole

                15.2.1.3. Other Anti-infectives

            15.2.2. Anti-inflammatory

                15.2.2.1. Prednisolone

                15.2.2.2. Tramadol

                15.2.2.3. Other Anti-inflammatory

            15.2.3. CNS Agents

                15.2.3.1. Potassium bromide

                15.2.3.2. Gabapentin

                15.2.3.3. Other CNS agents

            15.2.4. GI Drugs

                15.2.4.1. Apomorphine

                15.2.4.2. Ursodiol

                15.2.4.3. Cisapride

                15.2.4.4. Other GI Drugs

            15.2.5. Others

        15.3. Market Value Forecast, by Animal Type, 2017–2031

            15.3.1. Companion Animal

                15.3.1.1. Dogs

                15.3.1.2. Cats

                15.3.1.3. Others

            15.3.2. Live Stock

        15.4. Market Value Forecast, by Dosage Form, 2017–2031

            15.4.1. Capsules

            15.4.2. Solutions

            15.4.3. Powders

            15.4.4. Suspension

            15.4.5. Others

        15.5. Market Value Forecast, by Route of Administration, 2017–2031

            15.5.1. Oral

            15.5.2. Injectable

            15.5.3. Topical

            15.5.4. Rectal

            15.5.5. Ocular

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Country

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Product

            15.7.2. By Animal Type

            15.7.3. By Dosage Form

            15.7.4. By Route of Administration

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company, 2021

        16.3. Company Profiles

            16.3.1. Wedgewood Pharmacy

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Company Financials

                16.3.1.3. Growth Strategies

                16.3.1.4. SWOT Analysis

            16.3.2. Triangle Compounding Pharmacy

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Company Financials

                16.3.2.3. Growth Strategies

                16.3.2.4. SWOT Analysis

            16.3.3. Davis Islands Pharmacy

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Company Financials

                16.3.3.3. Growth Strategies

                16.3.3.4. SWOT Analysis

            16.3.4. Custom Med Compounding Pharmacy

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Company Financials

                16.3.4.3. Growth Strategies

                16.3.4.4. SWOT Analysis

            16.3.5. Central Compounding Center South

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Company Financials

                16.3.5.3. Growth Strategies

                16.3.5.4. SWOT Analysis

            16.3.6. Wellness Pharmacy of Cary

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Company Financials

                16.3.6.3. Growth Strategies

                16.3.6.4. SWOT Analysis

            16.3.7. Caringbah Compounding Pharmacy

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Company Financials

                16.3.7.3. Growth Strategies

                16.3.7.4. SWOT Analysis

            16.3.8. Millers Pharmacy

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Company Financials

                16.3.8.3. Growth Strategies

                16.3.8.4. SWOT Analysis

            16.3.9. Smith's Pharmacy

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Company Financials

                16.3.9.3. Growth Strategies

                16.3.9.4. SWOT Analysis

            16.3.10. Specialist Compounding Pharmacy Pte Ltd.

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Company Financials

                16.3.10.3. Growth Strategies

                16.3.10.4. SWOT Analysis

            16.3.11. Tache Pharmacy

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Company Financials

                16.3.11.3. Growth Strategies

                16.3.11.4. SWOT Analysis

    List of Tables

    Table 01: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 02: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 03: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031

    Table 04: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031

    Table 05: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031

    Table 06: Global Animal Drug Compounding Market Value (US$ My) Forecast, by Others, 2017–2031

    Table 07: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

    Table 08: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 09: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 10: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 11: Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Region, 2017–2031 

    Table 12: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 13: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 14: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 15: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031

    Table 16: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031

    Table 17: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031

    Table 18: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031

    Table 19: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

    Table 20: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031

    Table 21: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 22: North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 23: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 24: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 25: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 26: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031

    Table 27: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031

    Table 28: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031

    Table 29: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031

    Table 30: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

    Table 31: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031

    Table 32: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 33: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 34: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 35: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 36: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 37: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031

    Table 38: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031

    Table 39: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031

    Table 40: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031

    Table 41: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

    Table 42: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031

    Table 43: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 44: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 45: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 46: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 47: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 48: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031

    Table 49: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031

    Table 50: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031

    Table 51: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031

    Table 52: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

    Table 53: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031

    Table 54: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 55: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 56: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 57: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 58: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-infectives, 2017–2031

    Table 59: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2017–2031

    Table 60: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by CNS Agents, 2017–2031

    Table 61: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by GI Drugs, 2017–2031

    Table 62: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Others, 2017–2031

    Table 63: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

    Table 64: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Companion Animal, 2017–2031

    Table 65: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 66: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    List of Figures

    Figure 01: Global Animal Drug Compounding Market, by Product, 2021 and 2031

    Figure 02: Global Animal Drug Compounding Market Attractiveness Analysis, Product, 2022–2031

    Figure 03: Global Animal Drug Compounding Market (US$ Mn), by Anti-infectives, 2017–2031

    Figure 04: Global Animal Drug Compounding Market (US$ Mn), by Anti-inflammatory, 2017–2031

    Figure 05: Global Animal Drug Compounding Market (US$ Mn), by CNS Agents, 2017–2031

    Figure 06: Global Animal Drug Compounding Market (US$ Mn), by GI Drugs, 2017–2031

    Figure 07: Global Animal Drug Compounding Market (US$ Mn), by Others, 2017–2031

    Figure 08: Global Animal Drug Compounding Market, by Animal Type, 2021 and 2031

    Figure 09: Global Animal Drug Compounding Market Attractiveness Analysis, Animal Type, 2022–2031

    Figure 10: Global Animal Drug Compounding Market (US$ Mn), by Companion Animal, 2017–2031

    Figure 11: Global Animal Drug Compounding Market (US$ Mn), by Livestock Animal, 2017–2031

    Figure 12: Global Animal Drug Compounding Market, by Dosage Form, 2021 and 2031

    Figure 13: Global Animal Drug Compounding Market Attractiveness Analysis, Dosage Form, 2022–2031

    Figure 14: Global Animal Drug Compounding Market (US$ Mn), by Capsules, 2017–2031

    Figure 15: Global Animal Drug Compounding Market (US$ Mn), by Solutions, 2017–2031

    Figure 16: Global Animal Drug Compounding Market (US$ Mn), by Powders, 2017–2031

    Figure 17: Global Animal Drug Compounding Market (US$ Mn), by Suspension, 2017–2031

    Figure 18: Global Animal Drug Compounding Market (US$ Mn), by Others, 2017–2031

    Figure 19: Global Animal Drug Compounding Market, by Route of Administration, 2021 and 2031

    Figure 20: Global Animal Drug Compounding Market Attractiveness Analysis, Route of Administration, 2022–2031

    Figure 21: Global Animal Drug Compounding Market (US$ Mn), by Oral, 2017–2031

    Figure 22: Global Animal Drug Compounding Market (US$ Mn), by Injectable, 2017–2031

    Figure 23: Global Animal Drug Compounding Market (US$ Mn), by Topical, 2017–2031

    Figure 24: Global Animal Drug Compounding Market (US$ Mn), by Rectal, 2017–2031

    Figure 25: Global Animal Drug Compounding Market (US$ Mn), by Ocular, 2017–2031

    Figure 26: Global Animal Drug Compounding Market Value Share Analysis, by Region, 2021 and 2031

    Figure 27: Global Animal Drug Compounding Market Attractiveness Analysis, by Region, 2022–2031

    Figure 28: North America Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 29: North America Animal Drug Compounding Market Value Share Analysis, by Country, 2021 and 2031

    Figure 30: North America Animal Drug Compounding Market Attractiveness Analysis, by Country, 2022–2031

    Figure 31: North America Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031

    Figure 32: North America Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031

    Figure 33: North America Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031

    Figure 34: North America Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031

    Figure 35: North America Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031

    Figure 36: North America Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031

    Figure 37: North America Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 38: North America Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 39: Europe Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 40: Europe Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 41: Europe Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 42: Europe Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031

    Figure 43: Europe Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031

    Figure 44: Europe Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031

    Figure 45: Europe Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031

    Figure 46: Europe Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031

    Figure 47: Europe Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031

    Figure 48: Europe Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 49: Europe Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 50: Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 51: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 52: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 53: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031

    Figure 54: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031

    Figure 55: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031

    Figure 56: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031

    Figure 57: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031

    Figure 58: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031

    Figure 59: Asia Pacific Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 60: Asia Pacific Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 61: Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 62: Latin America Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 63: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 64: Latin America Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031

    Figure 65: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031

    Figure 66: Latin America Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031

    Figure 67: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031

    Figure 68: Latin America Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031

    Figure 69: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031

    Figure 70: Latin America Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 71: Latin America Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 72: Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 73: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 74: Middle East and Africa Animal Drug Compounding Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 75: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Product, 2021 and 2031

    Figure 76: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Product, 2022–2031

    Figure 77: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Animal Type, 2021 and 2031

    Figure 78: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Animal Type, 2022–2031

    Figure 79: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Dosage Form, 2021 and 2031

    Figure 80: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form, 2022–2031

    Figure 81: Middle East & Africa Animal Drug Compounding Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 82: Middle East & Africa Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved